Michael Chen

Switching From Donepezil to Rivastigmine Is Well Tolerated: Results of an Open-Label Safety and Tolerability Study.

C. Sadowsky, M. Farlow, D. Mirski, 2005, Primary care companion to the Journal of clinical psychiatry.

A Pilot Study Evaluating the Efficacy and Safety of Rivastigmine in Patients with Mixed Dementia

S. Potkin, G. Alva, D. Mirski, 2006, Drugs & aging.

The Validation of a Caregiver Assessment of Dementia: The Dementia Severity Scale

Philip D. Harvey, Philip D Harvey, Karin Coyne, 2005, Alzheimer disease and associated disorders.

Sensitivity analysis of a comparative trial of 6 month buprenorphine implants (probuphine) and sublingual buprenorphine in stable opioid-dependent patients

R. Rosenthal, F. Vocci, M. Lofwall, 2017 .

Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study

A. Rabinowicz, P. Aupperle, D. Mirski, 2004, Current medical research and opinion.

Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study.

J. Cummings, D. Mirski, B. Koumaras, 2005, The American journal of geriatric pharmacotherapy.

Long-Term Effects of Rivastigmine Treatment on the Need for Psychotropic Medications in Nursing Home Patients with Alzheimer’s Disease

K. Edwards, D. Mirski, B. Koumaras, 2005 .

Long-Term Buprenorphine Implants for Treatment of Opioid Dependence: Safety Outcomes from Two Open-Label Extension Trials

R. Rosenthal, W. Ling, R. Dammerman, 2017 .